NCT03052478已完成2 期
Phase II, Single-arm Study of Vismodegib in Advanced Gastric Adenocarcinoma Patients With SMO Overexpression
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Objective response rate (ORR) by RECIST 1.1
研究概览
简要总结
There is no accepted standard therapy for patients with advanced gastric cancer who have progressed during or after second-line therapy. The role of 3rd line treatment in advanced gastric cancer has not been proven.
As a novel target of gastric cancer, SMO overexpression is chosen in this study, and the investigators plan this study to evaluate the efficacy and safety of vismodegib in gastric cancer. The doses of vismodegib are based on trials of basal cell carcinoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Provision of fully informed consent prior to any study specific procedures.
- •Patients must be ≥20 years of age.
- •Advanced gastric adenocarcinoma (including GEJ) that has progressed during or after 1st line or second-line therapy.
- •Both fluoropyrimidine and platinum agent need to be contained in the prior chemotherapies
- •Prior adjuvant or neoadjuvant therapy is counted as 1 regimen, provided that disease progression occurs within 6 months after the completion of adjuvant or neoadjuvant therapy.
- •Acceptable prior chemotherapy regimens for this protocol are chemotherapy regimens that include Immune Target agent therapy. (such as a pembrolizumab, ramucirumab etc)
- •Have the presence of measurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
- •Patients with SMO overexpression by IHC
- •Patients are willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations.
- •ECOG performance status 0-
- •Patients must have a life expectancy ≥ 3 months from proposed first dose date.
- •Patients must have acceptable bone marrow, liver and renal function measured within 28 days prior to administration of study treatment as defined below:
- •Haemoglobin ≥9.0 g/dL (transfusion allowed)
- •Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
- •White blood cells (WBC) > 3 x 109/L
- •Platelet count ≥100 x 109/L (transfusion allowed)
- •Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (does not include patients with Glibert's disease)
- •AST (SGOT)/ALT (SGPT) ≤ 2.5 x institutional upper limit of normal unless liver metastases are present in which case it must be ≤ 5x ULN
- •Serum creatinine ≤1.5 x institutional ULN
- •Negative urine or serum pregnancy test within 28 days of study treatment, confirmed prior to treatment on day
- •for women of childbearing potential.
- •Provision of consent for mandatory biopsy at progression (fresh frozen will be mandatory if clinically feasible)
- •Provision of archival or fresh tissue sample at baseline (fresh frozen will be mandatory if clinically feasible)
排除标准
- •Patients will be excluded from the study if they meet any of the following criteria:
- •Are currently enrolled in, or discontinued within the last 21 days from, a clinical trial involving an investigational product or non-approved use of a drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
- •Any previous treatment with Hedgehog pathway inhibitor
- •Patients with second primary cancer, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for ≤5 years.
- •HER2 positive patients (defined by HER2 3+ by immunohistochemistry or HER2 SISH +)
- •Patients unable to swallow orally administered medication.
- •Treatment with any investigational product during the last 21 days before the enrollment (or a longer period depending on the defined characteristics of the agents used).
- •Patients receiving any systemic chemotherapy, radiotherapy (except for palliative reasons), within 3 weeks from the last dose prior to study treatment (or a longer period depending on the defined characteristics of the agents used). The patient can receive a stable dose of bisphosphonates or denusomab for bone metastases, before and during the study as long as these were started at least 4 weeks prior to treatment.
- •With the exception of alopecia, any ongoing toxicities (>CTCAE grade 1) caused by previous cancer therapy.
- •Intestinal obstruction or CTCAE grade 3 or grade 4 upper GI bleeding within 4 weeks before the enrollment.
- •Resting ECG with measurable QTcB > 480 msec on 2 or more time points within a 24 hour period or family history of long QT syndrome.
- •Patients with cardiac problem as follows: Atrial fibrillation with a ventricular rate >100 bpm on ECG at rest , Symptomatic heart failure (NYHA grade II-IV), Prior or current cardiomyopathy, Severe valvular heart disease, Uncontrolled angina (Canadian Cardiovascular Society grade II-IV despite medical therapy), Acute coronary syndrome within 6 months prior to starting treatment
- •Female patients who are breast-feeding or child-bearing and Male or female patients of reproductive potential who are not employing an effective method of contraception
- •Any evidence of severe or uncontrolled systemic disease, active infection, active bleeding diatheses or renal transplant, including any patient known to have hepatitis B, hepatitis C or human immunodeficiency virus (HIV) (HBV carrier is allowed)
研究组 & 干预措施
vismodegib arm
Experimental
. Vismodegib 150 mg will be administered orally once a day for 21 days as one cycle.
干预措施: Vismodegib 150 mg (Drug)
结局指标
主要结局
Objective response rate (ORR) by RECIST 1.1
时间窗: 6 months
次要结局
未报告次要终点
研究者
Jeeyun Lee
Professor
Samsung Medical Center
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Docetaxel and Epirubicin in Advanced Gastric CancerStomach NeoplasmsNCT00375999Yonsei University34
Unknown
2 期
S-1 Versus S-1 Plus Cisplatin as an Adjuvant Chemotherapy to Treat Gastric CancerGastric CancerNCT01426646Kyungpook National University Hospital218
已完成
1 期
Fibroblast Growth Factor (FGFs) / Fibroblast Growth Factor Receptor (FGFRs) Genetic as a Second-line Therapy for Recurrent / Progressive Gastric Cancer With INCB054828 and Paclitaxel a Study to Evaluate the Safety and Efficacy of Combination Therapy.Fibroblast Growth Factors (FGFs)/Fibroblast Growth Factor Receptors (FGFRs) Genetic Aberration Gastric Cancer, INCB054828, PaclitaxelNCT05529667Yonsei University15
Unknown
2 期
HLX07+HLX10+Chemotherapy or HLX07 Monotherapy in Patients With Advanced Metastatic Gastric CancerGastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ)NCT05246982Shanghai Henlius Biotech40
Unknown
2 期
A Phase II Study of Conversion Surgery After IP Paclitaxel With XELOX Chemotherapy in AGC With Peritoneal DisseminationAdvanced Gastric CancerPeritoneal CarcinomatosisNCT04797923Gangnam Severance Hospital43